Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 94 peer-reviewed journal articles Updated
Hepatology

Understanding Porphyria: Acute and Cutaneous Types

At a Glance

Porphyria is a rare metabolic disorder caused by a defect in heme production, leading to a toxic buildup of porphyrins. Acute types cause severe abdominal pain and nerve issues, while cutaneous types cause extreme sun sensitivity. Identifying your exact type and managing triggers is essential.

Receiving a diagnosis of porphyria can feel like being handed a puzzle with missing pieces. It is a rare and often misunderstood group of conditions, and it is completely normal to feel overwhelmed or even relieved to finally have a name for what you are experiencing. Because these conditions are rare, you may find that you quickly become more of an expert on your specific type than many general practitioners you encounter [1][2].

This guide is designed to help you navigate your diagnosis and empower you with the knowledge you need.

01

Symptoms and the Biology of Porphyria

Learn the biological causes of porphyria symptoms. Understand how heme pathway blockages trigger severe AHP stomach pain, PCT blisters, and EPP sun burning.

02

Diagnosing Porphyria: Crucial Lab Tests and Avoidable Mistakes

Learn how to correctly diagnose porphyria. Discover the crucial urine PBG and ALA tests for acute attacks, plasma scans for skin types, and common lab mistakes.

03

Managing Triggers: Preventing Acute Attacks

Learn how to prevent acute porphyria attacks and skin flares by managing key triggers. Understand medication safety, nutrition, hormones, and light protection.

04

Treatment Options for Acute and Cutaneous Porphyria

Learn about modern treatments for AHP, PCT, and EPP. Discover how IV hemin, Givosiran, phlebotomy, and afamelanotide help manage and prevent porphyria attacks.

05

Long-Term Health Risks and Liver Surveillance

Learn about the long-term health risks of Acute Hepatic Porphyria (AHP). Understand liver cancer surveillance, kidney disease monitoring, and nerve health.

What is Porphyria?

At its core, porphyria is a metabolic disorder involving heme, a vital component of hemoglobin that helps your blood carry oxygen [3]. Your body makes heme through a multi-step process. In porphyria, there is a “bottleneck” caused by a deficiency in one of the eight enzymes needed for this process [4][5].

When an enzyme isn’t working correctly, the building blocks (called porphyrins or precursors) cannot move through the “assembly line.” Instead, they back up and reach toxic levels in your liver or bone marrow, eventually leaking into your blood, skin, and organs, which causes symptoms [6][7].

Understanding the Two Main Categories

The impact of porphyria depends entirely on which enzyme is affected and where the buildup occurs. Doctors generally divide them into two major groups:

1. Acute Hepatic Porphyrias (AHP)

These types primarily affect the nervous system and the liver. The most common form is Acute Intermittent Porphyria (AIP) [8].

  • The Experience: Symptoms often come in “attacks”—sudden, severe episodes of intense abdominal pain that can be accompanied by nausea, vomiting, fast heart rate, and limb weakness [9][10].
  • The “Invisible” Nature: Because the pain is internal and doesn’t show up on standard imaging like X-rays or CT scans, these symptoms are often misdiagnosed as appendicitis or gallbladder issues [11][12].

2. Cutaneous Porphyrias

These types primarily affect the skin. The most common is Porphyria Cutanea Tarda (PCT), while others include Erythropoietic Protoporphyria (EPP) [13][14].

  • The Experience: These cause extreme sensitivity to sunlight (photosensitivity). Depending on the type, this can lead to painful blistering and fragile skin (in PCT) or a severe, “burning” or “stinging” sensation immediately upon sun exposure (in EPP) [6][15].
  • A Unique Overlap: Some types, like Variegate Porphyria, can actually cause both acute nerve attacks and skin blistering [16][17].

Why Most Doctors Haven’t Seen It

It is common for patients to face a diagnostic delay of 10 to 15 years [11]. Because porphyria is rare, many local doctors may only see one case in their entire career [1]. Since the symptoms (like stomach pain or sun rashes) look like many other common diseases, it is rarely the first thing a doctor suspects. This is not a reflection of your symptoms’ reality, but rather a result of the disease’s rarity and complexity.

Stabilizing Facts

While a porphyria diagnosis is life-changing, it is also a roadmap to feeling better.

  • Knowledge is Protective: Once you know your specific type, you can identify and avoid specific triggers—such as certain medications, fasting, or alcohol—that often cause attacks or flare-ups [18][19].
  • Treatment is Advancing: We are in a new era of porphyria care. Highly effective treatments, such as Givosiran for preventing acute attacks and Afamelanotide for increasing sun tolerance, have significantly improved quality of life [20][21].
  • Management is Life-Saving: With a diagnosis, you can now enter specialized monitoring. For example, people with acute types receive regular liver screenings to catch potential issues early, ensuring long-term health and safety [22][23].
  • Be Prepared: Because you may encounter doctors unfamiliar with porphyria, consider wearing a medical alert bracelet and carrying an emergency protocol letter from your specialist.

The most important next step is connecting with a specialist—typically a hepatologist (liver doctor) or hematologist (blood doctor) who focuses on porphyria—to confirm your specific type and create a personalized management plan [24][25].

Common questions in this guide

What is the difference between acute and cutaneous porphyria?
Acute hepatic porphyrias primarily affect the nervous system and liver, causing sudden, severe attacks of internal pain. Cutaneous porphyrias mainly affect the skin, leading to extreme sensitivity to sunlight, blistering, and fragile skin.
Why does it take so long to get a porphyria diagnosis?
Porphyria is very rare, so many doctors may only see one case in their career. The most common symptoms, like severe stomach pain or sun rashes, closely mimic other routine illnesses such as appendicitis or gallbladder issues, which often leads to misdiagnoses.
What lab tests are used to diagnose porphyria?
A diagnosis requires specific biochemical tests, such as testing urine for porphobilinogen (PBG) or checking plasma porphyrins. The internal pain caused by acute porphyria will not show up on standard imaging like X-rays or CT scans.
What are the most common triggers for a porphyria attack?
Common triggers include certain medications, fasting, alcohol consumption, and for cutaneous types, exposure to sunlight. Identifying and avoiding your specific triggers is one of the most effective ways to prevent attacks.
Are there treatments available for porphyria?
Yes, highly effective treatments are available. Medications like givosiran can help prevent acute attacks, while afamelanotide can increase sun tolerance for those with cutaneous forms. Your specialist will also monitor your long-term liver health.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my test results, do I have an Acute Hepatic Porphyria or a Cutaneous Porphyria?
  2. 2.Can you provide me with a 'safe' and 'unsafe' medication list from a recognized porphyria drug database?
  3. 3.Who is the nearest porphyria specialist or specialized center you can refer me to?
  4. 4.What specific biochemical tests (like urine PBG or plasma porphyrins) were used to confirm my diagnosis?
  5. 5.Are there specific triggers—like certain foods, medications, or stress—that I should prioritize avoiding?
  6. 6.If I have an acute type, what is our emergency plan if I experience a severe attack?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Neurological and neuropsychiatric manifestations of porphyria.

    Suh Y, Gandhi J, Seyam O, et al.

    The International journal of neuroscience 2019; (129(12)):1226-1233 doi:10.1080/00207454.2019.1655014.

    PMID: 31402774
  2. 2

    Acute variegate porphyria presenting with reversible cerebral vasoconstriction.

    Webb AJ, Ingale H, Irani SR, Hu MT

    Clinical neurology and neurosurgery 2016; (146()):102-4.

    PMID: 27186968
  3. 3

    Porphyrias in the Age of Targeted Therapies.

    Erwin AL, Balwani M

    Diagnostics (Basel, Switzerland) 2021; (11(10)) doi:10.3390/diagnostics11101795.

    PMID: 34679493
  4. 4

    Update on the Porphyrias.

    Dickey AK, Leaf RK, Balwani M

    Annual review of medicine 2024; (75()):321-335 doi:10.1146/annurev-med-042921-123602.

    PMID: 37540847
  5. 5

    Porphyria: What Is It and Who Should Be Evaluated?

    Edel Y, Mamet R

    Rambam Maimonides medical journal 2018; (9(2)) doi:10.5041/RMMJ.10333.

    PMID: 29553924
  6. 6

    [Porphyria].

    Stölzel U, Stauch T, Kubisch I

    Der Internist 2021; (62(9)):937-951 doi:10.1007/s00108-021-01066-1.

    PMID: 34185109
  7. 7

    Acute Hepatic Porphyria.

    Bissell DM, Wang B

    Journal of clinical and translational hepatology 2015; (3(1)):17-26 doi:10.14218/JCTH.2014.00039.

    PMID: 26357631
  8. 8

    Therapeutic approach to acute crises of hepatic porphyrias.

    Garrido Montes M, Pertusa Mataix R, Garcia Morillo JS

    Revista clinica espanola 2024; (224(10)):664-669 doi:10.1016/j.rceng.2024.09.004.

    PMID: 39313028
  9. 9

    The acute hepatic porphyrias.

    Wang B

    Translational gastroenterology and hepatology 2021; (6()):24 doi:10.21037/tgh-2020-01.

    PMID: 33824928
  10. 10

    EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks.

    Gouya L, Ventura P, Balwani M, et al.

    Hepatology (Baltimore, Md.) 2020; (71(5)):1546-1558 doi:10.1002/hep.30936.

    PMID: 31512765
  11. 11

    A Rare Clinical Presentation of Variegate Porphyria.

    Viakhireva I, Murtazina A, Orlova A, et al.

    Molecular genetics & genomic medicine 2026; (14(6)):e70243 doi:10.1002/mgg3.70243.

    PMID: 42281359
  12. 12

    Clinical Guide and Update on Porphyrias.

    Stölzel U, Doss MO, Schuppan D

    Gastroenterology 2019; (157(2)):365-381.e4 doi:10.1053/j.gastro.2019.04.050.

    PMID: 31085196
  13. 13

    Relapse of porphyria cutanea tarda after treatment with phlebotomy or 4-aminoquinoline antimalarials: a meta-analysis.

    Salameh H, Sarairah H, Rizwan M, et al.

    The British journal of dermatology 2018; (179(6)):1351-1357 doi:10.1111/bjd.16741.

    PMID: 29750336
  14. 14

    Porphyria: awareness is the key to diagnosis!

    Heymans B, Meersseman W

    Acta clinica Belgica 2022; (77(3)):703-709 doi:10.1080/17843286.2021.1918876.

    PMID: 33938396
  15. 15

    Ultraviolet A phototest positivity is associated with higher free erythrocyte protoporphyrin IX concentration and lower transferrin saturation values in erythropoietic protoporphyria.

    Genovese G, Maronese CA, Moltrasio C, et al.

    Photodermatology, photoimmunology & photomedicine 2022; (38(2)):141-149 doi:10.1111/phpp.12727.

    PMID: 34420239
  16. 16

    Understanding the Clinical Spectrum of the Cutaneous and Acute Hepatic Porphyrias.

    Vu TN, Talasila S, Jeha GM, et al.

    American journal of clinical dermatology 2026; (27(4)):745-764 doi:10.1007/s40257-026-01046-x.

    PMID: 42213346
  17. 17

    Understanding Hepatic Porphyrias: Symptoms, Treatments, and Unmet Needs.

    Balogun O, Nejak-Bowen K

    Seminars in liver disease 2024; (44(2)):209-225 doi:10.1055/s-0044-1787076.

    PMID: 38772406
  18. 18

    Porphyrias: A 2015 update.

    Karim Z, Lyoumi S, Nicolas G, et al.

    Clinics and research in hepatology and gastroenterology 2015; (39(4)):412-25.

    PMID: 26142871
  19. 19

    Best practice guidelines on first-line laboratory testing for porphyria.

    Woolf J, Marsden JT, Degg T, et al.

    Annals of clinical biochemistry 2017; (54(2)):188-198 doi:10.1177/0004563216667965.

    PMID: 27555665
  20. 20

    Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension study.

    Sardh E, Balwani M, Rees DC, et al.

    Orphanet journal of rare diseases 2024; (19(1)):365 doi:10.1186/s13023-024-03284-w.

    PMID: 39363243
  21. 21

    Challenges in the management of acute intermittent porphyria with recurrent attacks during pregnancy: A case report.

    Vassiliou D, Lempessi C, Harper P, Sardh E

    Clinical case reports 2020; (8(12)):2483-2487 doi:10.1002/ccr3.3185.

    PMID: 33363763
  22. 22

    Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review.

    Ramai D, Deliwala SS, Chandan S, et al.

    Cancers 2022; (14(12)) doi:10.3390/cancers14122947.

    PMID: 35740611
  23. 23

    Liver transplantation and primary liver cancer in porphyria.

    Lissing M, Wang B, Wahlin S

    Liver international : official journal of the International Association for the Study of the Liver 2025; (45(3)):e15894 doi:10.1111/liv.15894.

    PMID: 38456621
  24. 24

    International Porphyria Molecular Diagnostic Collaborative: an evidence-based database of verified pathogenic and benign variants for the porphyrias.

    Chen B, Whatley S, Badminton M, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(11)):2605-2613 doi:10.1038/s41436-019-0537-7.

    PMID: 31073229
  25. 25

    Guide for the classification of porphyrias using state-of-the-art reverse-phase high-performance liquid chromatography.

    Laguna J, Wijngaard R, Marés L, et al.

    Scandinavian journal of clinical and laboratory investigation 2025; (85(5)):327-339 doi:10.1080/00365513.2025.2524714.

    PMID: 40600928

This page provides educational information about acute and cutaneous porphyria. It is not a substitute for professional medical advice, and you should always consult a hepatologist or hematologist for personalized diagnosis and treatment.

Get notified when new evidence is published on Porphyria.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.